Sep. 22 at 2:01 AM
Iambic Therapeutics filed Monday for an initial public offering on the Nasdaq Global Select Market under the ticker IAM. The San Diego-based clinical-stage life sciences and technology company uses AI to develop new medicines and counts Nvidia among its investors.
Proceeds from the IPO are expected to support three early-stage oncology programs. Its lead candidate, IAM1363, is an oral small-molecule HER2 inhibitor currently in a Phase 1/1b trial for patients with advanced solid tumors carrying HER2 alterations.
Iambic expects to file Investigational New Drug applications for two additional programs, IAM217 and IAM-C1, in the fourth quarter of 2026.
The SEC filing did not disclose the number of shares to be offered or the expected price range. J.P. Morgan, Jefferies, BofA Securities and Citigroup are serving as underwriters, with a 30-day option to purchase additional shares.
$NVDA $C $JPM $BAC